What Are Research Peptides? A Regulatory and Analytical Explainer

Introduction

The phrase "research peptides" describes synthetic peptides that are supplied as research-use-only (RUO) materials for laboratory investigation. It is a category defined by how a material is labeled, marketed, and intended to be used, not by its chemistry: a research peptide may share its exact amino-acid sequence with a compound described in the peer-reviewed literature, or even with an approved drug, and still occupy an entirely different legal position. This explainer sets out what the category means, how US law draws the line between research materials and drugs, what "high purity" and "research grade" mean when they appear on a certificate of analysis, and how the materials are actually produced. It makes no claims about the properties or effects of any compound. Readers new to the underlying chemistry may find the general overview of what peptides are a useful starting point.

Research use only as a labeling category

"Research use only" is a labeling designation. It states that a material is intended solely for laboratory research.

Two points about the designation are often misunderstood. First, the FDA's only formal guidance on RUO labeling concerns in vitro diagnostic (IVD) products, the reagents and instruments used to test specimens taken from the body [1]. That guidance and the regulation it interprets, 21 CFR 809.10(c), apply to IVD products; they do not govern peptides and are not the source of the "research peptide" category. Second, and more important, an RUO label does not by itself decide a material's legal status. What decides that status is the intended-use doctrine described in the next section.

How US law defines a drug: the intended-use doctrine

The Federal Food, Drug, and Cosmetic Act defines a drug, in relevant part, as an article "intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals" or "intended to affect the structure or any function of the body of man or other animals" [2]. The definition turns on intent, not on chemistry. The same molecule can be a laboratory reagent in one setting and a drug in another, depending on what it is intended for.

The FDA's regulation on the meaning of "intended uses," 21 CFR 201.128, explains how that intent is established. It refers to "the objective intent of the persons legally responsible for the labeling of an article," which "may be shown by such persons' expressions, the design or composition of the article, or by the circumstances surrounding the distribution of the article," including "labeling claims, advertising matter, or oral or written statements" [3]. Intended use is therefore judged from all the circumstances of marketing taken together.

The practical consequence is that a research peptide remains a research material only so long as it is labeled, described, and offered as one. A supplier that pairs an RUO label with claims about effects in humans has, under 21 CFR 201.128, expressed an intended use that brings the article within the drug definition, regardless of what the label says.

Three categories that share a molecule

A given peptide sequence can appear in three legally distinct forms in the United States.

Approved peptide drugs

An approved peptide drug has passed through FDA premarket review under a new drug application or biologics license. The agency has evaluated its safety and effectiveness for a stated indication, its manufacturing under current good manufacturing practice, and its labeling. Reviews of the field count more than 80 peptide drugs that have reached the market worldwide since insulin, according to Muttenthaler and colleagues writing in Nature Reviews Drug Discovery in 2021 [4], and Wang and colleagues surveyed the current landscape of therapeutic peptides in Signal Transduction and Targeted Therapy in 2022 [5]. Approved peptide drugs are dispensed under prescription and are outside the scope of a research-peptide catalog.

Compounded drugs

Compounded drugs are prepared for individual patients by licensed pharmacists or physicians under section 503A of the FDCA, or by registered outsourcing facilities under section 503B [6, 7]. The FDA states plainly that "compounded drugs are not FDA-approved," meaning the agency "does not verify the safety, effectiveness or quality of compounded drugs before they are marketed" [8]. Compounding is nonetheless a regulated activity practiced by licensed professionals on prescription. It is a category of drug, not of research material.

Research-use-only peptides

A research peptide is neither of the above. It has not been reviewed by the FDA for any use, it is not prepared or dispensed under a prescription, and it is offered solely as a laboratory reference material. Its legal position depends entirely on its intended use being confined to research. The regulatory status of any individual peptide is a matter of public record and varies compound by compound.

What high purity means analytically

"High purity" and "research grade" are analytical descriptions of a batch of material. They are established by two complementary measurements, and each answers a different question.

HPLC purity: how much of the sample is the main component

High-performance liquid chromatography (HPLC) separates a dissolved sample into its components, which elute from a column at different times and are recorded as peaks. Purity is reported as the area of the main peak relative to the total area of all peaks; a figure of "98% by HPLC" means that the target compound accounted for that proportion of the detected material under the stated method [9]. Because the percentage depends on the column, detector, and conditions used, it is meaningful only alongside the method that produced it [10].

Mass spectrometry identity: whether the main component is the intended molecule

Mass spectrometry (MS) measures the mass-to-charge ratio of ionized molecules and thereby the molecular weight of the compound. For a synthetic peptide the observed mass is compared with the theoretical mass calculated from the intended sequence, and a match within instrument tolerance is consistent with the conclusion that the material has the intended composition [11]. HPLC and MS are frequently combined in a single LC-MS analysis for peptide characterization [12]. A high HPLC purity without a matching MS result confirms only that one component dominates the sample, not which component it is.

What purity does not say

A purity figure describes what a material analytically is. It says nothing about whether the material is suitable, safe, or appropriate for any use, and a research peptide of very high analytical purity is still a research peptide. Purity is also distinct from net peptide content: a lyophilized solid contains counterions and residual water in addition to the peptide, so the mass of peptide in a vial is lower than the gross mass even when the HPLC purity is high [13]. Readers interested in why the solid form is used will find the physical chemistry set out in the article on why peptides are lyophilized.

What a certificate of analysis covers

A certificate of analysis (COA) is the document that records the analytical results for a specific batch. A credible COA is batch-specific, tied to the lot by a batch number, and method-transparent, naming the techniques and conditions used [14]. Its principal fields are identity (typically the MS result compared with the theoretical mass), purity (the HPLC percentage and its method), the batch or lot number, the test date, and an authorizing laboratory identifier. Testing performed by a laboratory independent of the supplier, ideally one accredited to ISO/IEC 17025, adds weight because it removes the supplier's own interest from the result [14]. A field-by-field guide appears in the article on certificates of analysis and third-party testing. In this catalog, for example, BPC-157 reference material and TB-500 reference material are each listed with a per-batch COA reporting HPLC purity and MS identity.

How research peptides are produced

Nearly all research peptides are made by solid-phase peptide synthesis (SPPS), the method Merrifield introduced in the Journal of the American Chemical Society in 1963 [15] and later reviewed in Science in 1986 [16]. In SPPS the growing chain is anchored to an insoluble resin bead. Each round of synthesis removes the protecting group from the free amine at the end of the chain, couples the next protected amino acid, and washes away excess reagents; because the peptide stays attached to the solid support, purification between steps is reduced to filtration. When the full sequence has been assembled, the peptide is cleaved from the resin and its side-chain protecting groups are removed.

The crude product contains the target peptide together with deletion sequences, incompletely deprotected species, and other process-related impurities. It is purified by preparative reversed-phase HPLC, and the collected fractions are usually freeze-dried to yield a lyophilized solid. Andersson and colleagues described the chemistry, purification, and scale-up considerations of the process in Biopolymers in 2000 [13]. The purified material is then characterized by analytical HPLC and mass spectrometry, producing the purity and identity data that appear on its certificate of analysis. The same synthetic chemistry underlies many approved peptide drugs; what differs is the regulatory pathway, manufacturing controls, and intended use.

Regulatory framing

Research peptides are sold under an RUO designation and are not approved by the FDA for any use in humans or animals. They are not drugs, dietary supplements, or foods, and they are not an alternative to approved or compounded medicines. Their legal status as research materials rests on the intended-use doctrine of 21 CFR 201.128, which looks to all the circumstances of marketing, and on the FDCA definition of a drug at 21 U.S.C. 321(g) [2, 3]. The existence of published research on a peptide does not establish that it is approved, safe, or effective for any application in humans, and analytical purity, however high, is a description of the material rather than a statement about its use.

Summary

Research peptides are synthetic peptides offered as research-use-only laboratory materials. The category is defined by intended use rather than chemistry: US law classifies an article as a drug according to the objective intent shown by all the circumstances of its marketing, so a research peptide remains one only while it is labeled and described as a research material. It is distinct from an approved peptide drug, which has passed FDA review, and from a compounded drug, which is prepared by licensed professionals under sections 503A and 503B. "High purity" is an analytical statement established by HPLC (how much of the sample is the main component) and mass spectrometry (whether that component has the intended mass), recorded on a batch-specific certificate of analysis. The materials are produced by solid-phase peptide synthesis, purified by HPLC, and supplied as lyophilized solids. None of this speaks to safety or efficacy in humans; it describes what a research peptide is.

References

1. U.S. Food and Drug Administration. Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Guidance for Industry and Food and Drug Administration Staff. November 2013. FDA guidance (applies to in vitro diagnostic products; cited here only as the origin of the RUO labeling concept)
2. 21 U.S.C. 321(g)(1). Federal Food, Drug, and Cosmetic Act, definition of "drug." Legal Information Institute, Cornell Law School
3. 21 CFR 201.128. Meaning of "intended uses." Legal Information Institute, Cornell Law School
4. Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325. DOI: 10.1038/s41573-020-00135-8 (PMID: 33536635)
5. Wang L, Wang N, Zhang W, et al. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022;7(1):48. DOI: 10.1038/s41392-022-00904-4 (PMID: 35165272)
6. 21 U.S.C. 353a. Pharmacy compounding (FDCA section 503A). Legal Information Institute, Cornell Law School
7. 21 U.S.C. 353b. Outsourcing facilities (FDCA section 503B). Legal Information Institute, Cornell Law School
8. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA
9. Moffatt F, Senkans P, Ricketts D. Approaches towards the quantitative analysis of peptides and proteins by reversed-phase high-performance liquid chromatography in the absence of a pure reference sample. J Chromatogr A. 2000;891(2):235-242. DOI: 10.1016/s0021-9673(00)00620-8 (PMID: 11043783)
10. Molina-Martin M, Marin A, Rivera-Sagredo A, Espada A. Liquid chromatography-mass spectrometry and related techniques for purity assessment in early drug discovery. J Sep Sci. 2005;28(14):1742-1750. DOI: 10.1002/jssc.200500107 (PMID: 16224969)
11. Strupat K. Molecular weight determination of peptides and proteins by ESI and MALDI. Methods Enzymol. 2005;405:1-36. DOI: 10.1016/S0076-6879(05)05001-9 (PMID: 16413308)
12. Lian Z, Wang N, Tian Y, Huang L. Characterization of Synthetic Peptide Therapeutics Using Liquid Chromatography-Mass Spectrometry: Challenges, Solutions, Pitfalls, and Future Perspectives. J Am Soc Mass Spectrom. 2021;32(8):1852-1860. DOI: 10.1021/jasms.0c00479 (PMID: 34110145)
13. Andersson L, Blomberg L, Flegel M, Lepsa L, Nilsson B, Verlander M. Large-scale synthesis of peptides. Biopolymers. 2000;55(3):227-250. DOI: 10.1002/1097-0282(2000)55:3<227::AID-BIP50>3.0.CO;2-7 (PMID: 11074417)
14. International Organization for Standardization. ISO/IEC 17025:2017. General requirements for the competence of testing and calibration laboratories. Geneva: ISO; 2017. ISO
15. Merrifield RB. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. DOI: 10.1021/ja00897a025
16. Merrifield B. Solid phase synthesis. Science. 1986;232(4748):341-347. DOI: 10.1126/science.3961484 (PMID: 3961484)